Design Therapeutics to Participate in the 2024 RBC Capital Markets Global Healthcare Conference
Rhea-AI Summary
Design Therapeutics, a biotechnology company focused on treating degenerative genetic diseases, will be participating in the 2024 RBC Capital Markets Global Healthcare Conference. The company's management will be involved in a fireside chat scheduled for May 15, 2024, at 11:30 a.m. ET in New York. The event will be live webcasted and archived for 30 days.
Positive
- None.
Negative
- None.
News Market Reaction – DSGN
On the day this news was published, DSGN gained 28.49%, reflecting a significant positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
CARLSBAD, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in a fireside chat at the 2024 RBC Capital Markets Healthcare Conference on Wednesday, May 15, 2024, at 11:30 a.m. ET in New York.
A live webcast of the fireside chat will be available here and in the investors section of the company’s website at www.designtx.com. The webcast will be archived for 30 days following the presentation.
About Design Therapeutics
Design Therapeutics is a biotechnology company developing a new class of therapies based on its platform of GeneTAC™ gene targeted chimera small molecules. The company’s GeneTAC™ molecules are designed to either dial up or dial down the expression of a specific disease-causing gene to address the underlying cause of disease. In addition to its lead GeneTAC™ small molecule, DT-216, in development for patients with Friedreich ataxia, the company is advancing programs in Fuchs endothelial corneal dystrophy, Huntington’s disease and myotonic dystrophy type-1. Discovery efforts are underway for multiple genomic medicines. For more information, please visit designtx.com.
Contact:
Renee Leck
THRUST Strategic Communications
renee@thrustsc.com